improv
vaccin
adjuv
develop
reduc
threat
pose
terrorist
attack
involv
aerosol
anthrax
spore
nevertheless
uncertainti
persist
concern
rel
benefit
induc
mucos
vs
system
immun
host
surviv
follow
inhal
exposur
anthrax
spore
work
examin
effect
deliv
licens
human
vaccin
anthrax
vaccin
adsorb
ava
combin
cpg
oligodeoxynucleotid
odn
adjuv
intraperiton
intranas
aj
mice
result
indic
protect
inhal
anthrax
correl
induct
strong
system
rather
mucos
immun
respons
demonstr
protect
significantli
improv
acceler
addit
cpg
odn
bacillu
anthraci
aerob
gramposit
sporeform
bacterium
found
natur
wild
domest
anim
b
anthraci
spore
highli
resist
environment
degrad
upon
germin
produc
tripartit
toxin
reduc
abil
host
immun
system
elimin
pathogen
human
exposur
anthrax
typic
aris
follow
contact
infect
livestock
gener
result
mild
form
cutan
diseas
contrast
inhal
exposur
anthrax
caus
sever
rapidli
progress
diseas
culmin
death
anthrax
vaccin
adsorb
ava
anthrax
vaccin
licens
human
use
us
approv
base
abil
reduc
suscept
cutan
anthrax
exposur
releas
anthrax
spore
design
aerosol
deliveri
bioterrorist
result
morbid
mortal
panic
underscor
need
improv
speed
efficaci
vaccineinduc
protect
inhal
exposur
ava
prepar
adsorb
cultur
filtrat
attenu
toxinogen
nonencapsul
strain
b
anthraci
onto
aluminum
hydroxid
studi
show
protect
ag
pa
core
anthrax
toxin
major
immunogen
ava
antibodi
ab
pa
neutral
toxin
inhibit
spore
germin
improv
phagocytosi
kill
spore
macrophag
licens
ava
vaccin
administ
seri
immun
month
follow
yearli
booster
schedul
induc
protect
serum
ab
titer
somewhat
slowli
link
advers
side
effect
synthet
oligodeoxynucleotid
odn
contain
immunostimulatori
cpg
motif
shown
boost
immun
coadminist
vaccin
includ
ava
cpg
odn
induc
function
matur
profession
ag
present
cell
apc
trigger
product
immunostimulatori
cytokin
chemokin
although
previou
studi
show
ad
cpg
odn
ava
boost
protect
among
anim
challeng
system
anthrax
effect
mucos
immun
protect
aerosol
anthrax
spore
never
evalu
current
work
examin
whether
ava
alon
coadminist
cpg
odn
improv
host
resist
inhal
anthrax
examin
rel
contribut
mucos
vs
system
immun
host
surviv
phosphorothio
cpg
odn
gctagacgttagcgt
control
odn
gctagagcttagcgt
synthes
cber
core
facil
free
endotoxin
protein
contamin
singl
lot
clinic
grade
ava
use
experi
bioport
corpor
east
lans
mi
recombin
pa
rpa
provid
usamriid
fort
detrick
md
prepar
describ
b
anthraci
strain
toxinogen
nonencapsul
use
prepar
stern
strain
spore
describ
specif
pathogen
free
male
aj
mice
obtain
nci
frederick
md
hous
steril
microisol
cage
barrier
environ
immun
wk
age
anim
experi
conduct
use
acuc
approv
protocol
aerosol
challeng
studi
perform
facil
male
aj
mice
immun
intraperiton
ip
intranas
ul
ava
ug
cpg
odn
final
volum
ul
ava
dose
select
basi
preliminari
studi
demonstr
ul
ava
induc
detect
suboptim
igg
antipa
respons
ul
ava
induc
respons
protect
mice
subsequ
anthrax
challeng
maximum
dose
ava
use
limit
volum
vaccin
could
safe
administ
mice
serum
obtain
tail
nick
store
c
use
bal
collect
instil
remov
ml
pb
lung
anesthet
mice
copra
ig
obtain
physic
disrupt
fecal
pellet
follow
suspens
votex
cocktail
proteas
inhibitor
includ
benzenesulfonyl
fluorid
aebsf
bestatin
leupeptin
aprotinin
edta
sigma
st
loui
mo
previous
describ
supernat
collect
centrifug
store
c
use
mice
challeng
via
aerosol
rout
lethal
dose
sti
spore
suspend
sti
spore
spore
aerosol
gener
use
sixjet
collison
nebul
bgi
incorpor
waltham
distribut
individu
mice
use
noseonli
exposur
system
ch
technolog
westwood
nj
previous
describ
prior
challeng
mice
suppli
fresh
air
allow
respiratori
rate
normal
surviv
monitor
day
igg
iga
antipa
ab
titer
monitor
describ
briefli
microtit
plate
immulon
thermo
labsystem
franklin
coat
ugml
rpa
pb
c
overnight
plate
block
nonfat
dri
milk
pb
contain
plate
wash
overlaid
serial
dilut
bal
serum
fecal
extract
h
room
temperatur
thorough
wash
bound
ab
detect
ad
hrplabel
goat
antimous
igg
iga
southern
biotechnolog
birmingham
al
follow
abt
substrat
kirkegaard
perri
gaithersburg
md
ab
titer
determin
comparison
standard
curv
gener
use
pool
sera
hyperimmun
mice
express
reciproc
end
point
dilut
follow
background
subtract
sampl
analyz
duplic
differ
kinet
develop
antipa
immun
respons
examin
use
twoway
anova
differ
igg
antipa
respons
induc
variou
vaccineadjuv
combin
assess
oneway
anova
differ
surviv
evalu
use
log
rank
analysi
kaplanmei
curv
correl
coeffici
determin
linear
regress
analysi
initi
studi
compar
abil
ava
deliv
system
ip
vs
mucos
rout
protect
aerosol
challeng
anthrax
spore
aj
mice
select
evalu
anim
mount
strong
ab
respons
ava
cpg
odn
ii
highli
suscept
challeng
attenu
sti
anthrax
spore
due
defect
complement
cascad
mice
immun
ava
cpg
odn
magnitud
result
mucos
immun
respons
analyz
monitor
antipa
ab
present
pulmonari
brochioalveolar
lavag
fluid
bal
andor
fecal
pellet
contain
copra
ig
secret
gut
lumen
seen
tabl
ia
agspecif
copra
iga
level
correl
close
pulmonari
iga
level
vaccin
mice
r
p
sinc
mice
surviv
collect
bal
experi
design
assess
effect
vaccin
surviv
post
challeng
reli
copra
antipa
titer
monitor
mucos
immun
system
immun
examin
monitor
serum
igg
antipa
titer
previou
studi
show
serum
igg
antipa
titer
repres
sensit
specif
marker
protect
sti
anthrax
spore
aj
mice
immun
ava
cpg
odn
significantli
higher
antipa
ab
titer
produc
mice
vaccin
rather
ul
ava
p
tabl
ad
cpg
odn
intranas
administ
ava
significantli
boost
bal
copra
iga
antipa
titer
fold
increas
p
tabl
ia
fig
intranas
deliveri
ava
cpg
odn
elicit
higher
consist
mucos
respons
system
vaccin
fig
p
contrast
ip
immun
ava
plu
cpg
odn
induc
significantli
stronger
serum
igg
antipa
respons
deliveri
dose
vaccin
fold
higher
p
tabl
ib
fig
ad
cpg
odn
system
administ
ava
significantli
boost
serum
ab
respons
approxim
p
tabl
ib
fig
mice
vaccin
either
ip
ava
cpg
odn
challeng
wk
later
ld
aerosol
stern
strain
anthrax
spore
sti
dose
sti
spore
uniformli
fatal
unimmun
control
seen
fig
mice
vaccin
ul
ava
cpg
odn
ip
rout
surviv
challeng
wherea
half
immun
vaccin
rout
ava
alon
ip
succumb
infect
p
significantli
higher
surviv
also
observ
ul
dose
ava
cpg
odn
deliv
compar
ip
p
fig
pursu
observ
addit
mice
vaccin
antipa
ab
respons
evalu
immedi
prior
sti
spore
challeng
consist
earlier
find
system
immun
enhanc
immun
vs
ul
ava
p
vaccin
via
ip
rather
rout
p
inclus
cpg
odn
vaccin
adjuv
p
tabl
ib
moreov
serum
mucos
antipa
titer
predict
surviv
follow
aerosol
sti
challeng
fig
p
wherea
nearli
mice
system
igg
antipa
titer
time
challeng
surviv
titer
surviv
fig
contrast
signific
correl
copra
iga
antipa
titer
surviv
p
fig
previou
studi
suggest
addit
cpg
odn
ava
acceler
boost
induct
pathogenspecif
immun
studi
examin
suscept
mice
system
anthrax
challeng
day
ava
vaccin
determin
whether
addit
cpg
odn
ava
acceler
induct
protect
immun
aerosol
spore
challeng
aj
mice
immun
ava
cpg
odn
respons
inhal
challeng
evalu
day
later
consist
prior
result
serum
igg
antipa
respons
magnifi
acceler
addit
cpg
odn
ava
fig
day
serum
antipa
titer
higher
ava
cpg
odn
vaccin
group
protect
significantli
enhanc
vs
p
note
although
igg
ab
titer
differ
group
day
p
signific
differ
surviv
still
observ
mice
challeng
earli
time
point
p
wilcoxin
log
rank
test
find
suggest
host
suscept
inhal
anthrax
influenc
magnitud
serum
antipa
respons
cours
infect
rather
simpli
time
initi
exposur
anthrax
spore
design
inhal
exposur
intent
releas
us
result
morbid
panic
establish
viabil
anthrax
bioterror
weapon
emphas
need
improv
speed
effici
protect
immun
induc
aerosol
anthrax
supplement
develop
novel
vaccin
adjuv
cpg
odn
valu
clarifi
role
mucos
system
immun
provid
protect
inhal
anthrax
toward
end
effect
system
vs
mucos
deliveri
ava
cpg
odn
evalu
strong
system
igg
antipa
ab
respons
elicit
follow
intraperiton
immun
consist
previou
report
fig
intranas
vaccin
use
elicit
mucos
immun
base
previou
report
show
techniqu
effect
stimul
pulmonari
ab
product
tabl
altern
administ
ava
intratrach
consid
unnecessarili
invas
cber
anim
care
use
committe
util
vaccin
establish
initi
studi
show
mice
immun
ul
ava
cpg
odn
mount
strong
mucos
respons
high
level
iga
antipa
ab
detect
lung
gi
tract
tabl
fig
consist
previou
report
bal
copra
ab
titer
correl
significantli
follow
vaccin
tabl
sinc
copra
ab
level
could
monitor
without
harm
mice
wherea
collect
bal
fatal
former
reli
upon
assess
mucos
immun
mice
subsequ
util
pathogen
challeng
studi
induct
humor
immun
evalu
compar
rel
chang
copra
bal
serum
ab
level
induc
vaccin
sourc
ab
evalu
independ
sinc
difficult
compar
ab
contain
fluid
collect
differ
site
note
method
section
bal
harvest
infus
lung
pb
copra
ig
dilut
fecal
pellet
cocktail
proteas
inhibitor
ab
collect
mucos
site
thu
dilut
present
serum
addit
ab
secret
gi
tract
persist
short
period
dictat
transit
time
gut
wherea
ab
secret
serum
accumul
period
week
current
work
establish
system
ab
titer
correl
resist
aerosol
anthrax
spore
mucos
ab
titer
even
among
mice
protect
challeng
immun
resist
correl
system
rather
mucos
ab
level
dose
ava
cpg
deliv
ip
protect
elicit
effect
system
vs
mucos
immun
fig
current
find
support
sever
addit
conclus
first
intraperiton
immun
induc
higher
system
lower
mucos
ab
respons
intranas
immun
tabl
fig
second
addit
cpg
odn
significantli
increas
magnitud
antipa
respons
elicit
rout
immun
tabl
fig
final
addit
cpg
odn
ava
significantli
reduc
host
suscept
infect
aerosol
anthrax
within
day
administr
fig
result
indic
effect
mediat
induct
innat
immun
respons
cpg
odn
sinc
none
mice
treat
cpg
odn
alon
surviv
challeng
rather
hypothes
surviv
influenc
cumul
serum
antipa
respons
cours
infect
rather
sole
time
pathogen
exposur
thu
vaccin
capabl
acceler
induct
protect
ab
host
subsequ
infect
may
reduc
morbid
mortal
long
initi
ab
respons
wane
studi
design
test
hypothesi
determin
whether
coadminist
cpgadjuv
ava
plu
antibiot
protect
mice
immedi
anthrax
exposur
underway
cpg
odn
interact
immun
cell
express
tlr
trigger
innat
immun
respons
character
product
proinflammatori
cytokin
chemokin
function
matur
apc
previou
studi
show
combin
cpg
odn
system
administ
ava
acceler
increas
product
serum
igg
antipa
ab
therebi
improv
protect
system
anthrax
challeng
result
phase
clinic
studi
show
ad
cpg
odn
ava
boost
serum
igg
antipa
respons
normal
human
volunt
fold
acceler
induct
immun
approxim
week
p
paramet
trial
signific
differ
report
frequenc
sever
advers
event
recipi
ava
plu
cpg
odn
vs
ava
alon
although
mildmoder
advers
event
includ
pain
warmth
swell
inject
site
system
effect
fever
fatigu
slightli
frequent
former
group
current
find
establish
serum
rather
mucos
ab
level
predict
resist
aerosol
anthrax
also
indic
serum
ab
titer
may
provid
surrog
marker
protect
aerosol
anthrax
spore
combin
ava
plu
cpg
odn
significantli
increas
antipa
ab
titer
acceler
induct
protect
immun
confer
signific
increas
surviv
within
day
vaccin
follow
anthrax
attack
less
half
potenti
expos
individu
complet
recommend
cours
antibiot
thu
vaccin
individu
risk
exposur
anthrax
cpgadjuv
ava
perhap
combin
shortterm
antibiot
therapi
might
prevent
pathogen
dissemin
optim
speed
reliabl
individu
develop
protect
immun
respons
mice
protect
develop
even
serum
ab
titer
began
rise
indic
magnitud
ab
respons
cours
infect
rather
sole
time
challeng
determin
host
surviv
assert
herein
privat
one
author
constru
offici
reflect
view
dtra
nci
larg
support
work
provid
part
joint
scienc
technolog
offic
chemic
biolog
defens
defens
threat
reduct
agenc
administ
ul
ava
cpg
odn
ip
result
surviv
compar
surviv
administ
mice
immun
ul
ava
cpg
odn
surviv
note
surviv
correl
significantli
serum
igg
p
mucos
antipa
titer
